Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eneapharm has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution activity is confined to 1 distinct examiner and 1 distinct art unit. This suggests a specific focus for the company's current patent applications. This level of concentration allows the applicant to focus their legal resources on a point of interaction within the patent office for their biotechnology claims.
The busiest examiner, GREENE, IVAN A, oversees 1 busiest examiner pending office action. Because the portfolio contains only 1 pending office action, GREENE, IVAN A is the examiner currently reviewing the company's work. The outcome of the company's active prosecution is therefore dependent on the specific interactions with this examiner in the assigned art unit. Practitioners should prioritize a thorough understanding of the approach taken by GREENE, IVAN A to the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.8% | +6.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040360 | INTESTINAL-RELEASE FORMULATION OF A DIGESTIVE ENZYME, METHOD OF PRODUCTION AND GALENIC PREPARATION | GREENE, IVAN A | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17040360 | INTESTINAL-RELEASE FORMULATION OF A DIGESTIVE ENZYME, METHOD OF PRODUCTION AND GALENIC PREPARATION | GREENE, IVAN A | 1619 | §103§112 | Non-Final OA | — | Pending | Jan 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEneapharm has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ivan A Greene has the most, with 1 of Eneapharm's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
